KalVista Pharmaceuticals (KALV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on the stock and has a $22.00 price target.
Tazeen Ahmad has given his Buy rating due to a combination of factors surrounding KalVista Pharmaceuticals’ strategic positioning in the acute hereditary angioedema (HAE) market. The company is preparing to launch its US commercial strategy for sebetralstat, which, if approved, would be the first orally dosed acute therapy available. This innovation is expected to drive significant market uptake due to its efficacy and safety profile, comparable to injectable treatments.
Furthermore, the success of Biocryst’s Orladeyo, the first oral prophylactic treatment for HAE, provides a positive precedent, suggesting strong commercial potential for sebetralstat. Ahmad assigns a 75% likelihood of success to the program and projects peak risk-adjusted sales of $604 million by fiscal year 2035. These factors, combined with updates to the company’s financial model and the full onboarding of their field sales team, support the Buy rating and a price objective of $22.
In another report released on March 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALV in relation to earlier this year.